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Epilepsy is a neurological disorder characterized by repeated seizures. 
Nowadays drugs and other approaches to reduce them are available but, 
unfortunately, around 30% of patients do not respond to medical therapies. In the last 
decade, optogenetics has emerged as a tool to both explore neuronal networks 
dynamics and to treat neurological conditions such as epilepsy. The optogenetics 
strategy involves the expression, in precise brain areas, of light sensitive proteins 
called opsins that are able to change the membrane potential upon wavelength-
specific illumination. This last aspect is, usually, achieved using LED-based 
hardware. Despite the many advantages of this technique, it still faces practical and 
translational challenges because of the difficulties of illuminating multiple and deep 
areas of the brain. In this scenario, the search of alternative light sources is a goal to 
achieve. Luciferases are enzymes able to emit light upon addittion of their own 
substrate coelenterazine, and can be used to deliver light to opsins and modulate their 
action. In this work, the probe called pHIL (pH sensitive inhibitory luminopsin) was 
developed with the purpose to modulate the epileptic phenotype. pHIL is composed 
of a bioluminescent protein, RLuc8, coupled to the inhibitory opsin eNpHR3.0. 
Moreover, the control of seizures will occur only under the intracellular acidic 
conditions observed in epileptic neurons. The pH sensitivity of the probe is given by 
the presence of a pH sensor, a pH-sensitive variant of EGFP, called E2GFP. The 
functioning of the probe is based on the BRET mechanism. The UV light that comes 
from the luciferase is transferred to the E2GFP that under acidic conditions will emit 
light and activate the eNpHR3.0, promoting membrane hyperpolarization of epileptic 
neurons. pHIL is expressed and localizes at the plasma membrane in both HEK293T 
cells and primary hippocampal neurons. Moreover, pHIL hyperpolarizes HEK293T 
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under acidic conditions and upon addition of CTZ 400a, the specific luciferase 
substrate able to induce UV light emission. On the basis of our data, therefore, we 





1.1 Neuronal excitability and pH. 
Brain cells are highly sensitive to a vast number of chemical factors, either 
exogenous such as drugs or toxins, or intrinsic such as neurotransmitters and 
hormones. One of the most important intrinsic neuromodulator is the H+ ion that can 
influence, in a very powerful way, neuronal function. The negative logarithm of H+ 
ion concentration (pH) is a fundamental cellular parameter that is critical to a series of 
processes including cell division, metabolism, apoptosis, and cell migration1–3 but 
also neuronal function and, in particular, synaptic transmission. 
The central role of pH in the control of synaptic transmission depends on the 
high pH sensitivity of a large number of molecules including various types of voltage 
and ligand gated channels, ion pumps and carriers. At the presynaptic side, for 
instance, it is known that the initial rise in the presynaptic calcium concentration 
mediated via voltage-gated calcium channels is pH dependent, as the opening and the 
conductivity of presynaptic voltage-gated calcium channels strongly depends on both 
extracellular and intracellular pH4. Protons bind sensors near the pore of the channel, 
thus reducing channel conductance and shift the channel activation voltage to more 
positive values. A central role in the increase of presynaptic calcium coming from 
intracellular stores is played by inositol 1,4,5-trisphosphate5 and ryanodine receptors6, 
whose activity is strongly pH dependent. 
At the postsynaptic side, instead, the N-methyl-D-aspartate-sensitive ionotropic 
glutamate receptors (NMDARs) are strongly modulated by changes in extracellular 
pH: a decrease in extracellular pH inhibits the ion channel function; on the contrary, 
an increase of extracellular pH activates the channel7. In contrast, kinetics and 
amplitudes of ɑ-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 
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Kainate receptors-mediated currents are only marginally modulated by alteration of 
extracellular pH. In this respect, protons inhibit AMPA receptor function by 
enhancing receptor desensitization8. In addition, γ-aminobutyric acid (GABA) 
receptor activity is modulated by pH. GABAA receptor-mediated currents are 
enlarged at low extracellular pH, whereas a high pH inhibits the GABA response9. 
GABAA receptors are also permeable to bicarbonate ions (HCO3
 –). In contrast to the 
direction of chloride fluxes, which vary depending on the existing chloride gradients, 
modulated by the cation-chloride co-transporters NKCC1 and KCC2, the existing 
gradients always drive HCO3
 – out of the neurons under physiological conditions. 
Therefore, the opening of a GABAA channel will result in an HCO3
 – efflux, leading 
to intracellular acidification and extracellular alkalization. Consequently, GABAergic 
transmission itself can cause alterations of both intra- and extracellular pH. 
From these and other evidences it is therefore clear that pH modulates neuronal 
excitability. Thus, the pH homeostasis in the brain must be tightly regulated. 
 
1.2 Regulation of pH homeostasis in the brain. 
Cellular pH homeostasis is established by active transport or buffering. Steady 
state intracellular pH (pHi) is dependent on the balance between the rate of acid 
loading and the rate of acid extrusion. In neurons acid loading processes are able to 
restore the steady state pHi after alkalinization and consist in the accumulation of H
+ 
generated through anaerobic or aerobic metabolism during neuronal firing or in the 
extrusion of HCO3
– from cells thanks to the action of Cl-HCO3 exchangers, mainly 
the Anion Exchanger 3 (AE3), which typically extrudes HCO3
- in exchange for 
extracellular Cl-. Acid extrusion, on the contrary, is a process that tends to raise pHi 
and in neurons it is usually achieved by the action of the SLC4 and SLC9 families of 
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Na+-coupled transport proteins. These transporter families take advantage of the Na+ 
inward gradient established by the Na+/K+ ATPase to extrude H+ from the cell or 
accumulate a weak base (HCO3
–) in the intracellular side (in the case of Na+/HCO3
– 
cotransporters). The main H+ extruder is the Na+/H+ Exchanger Type 1 (NHE1). It is 
expressed in all mammalian cell types and is a primary regulator of intracellular pH 
homeostasis and cell volume10. The major function of NHE1 is to contrast excessive 
intracellular acidification and maintain the acid–base balance in the cytoplasm. In 
hippocampal and cortical neurons, NHE1 is mainly activated by a decrease in 
intracellular pH11. When intracellular acidosis occurs, NHE1 activation is 
indispensable for the extrusion of H+ to restore the physiological intracellular pH. 
Na+/HCO3
– co-transporters also mediate acid extrusion. The co-transporter Slc4a4 
and Slc4a7 are expressed in the nervous system; in particular, Slc4a7 is shown to co-
localize with PSD-95, a postsynaptic protein of glutamatergic synapses, and its 
expression is increased upon metabolic acidosis12. 
The importance of acid loaders and extruders in the maintenance of neuronal 
homeostasis is underlined when phenotypes of transporters or exchangers knock out 
mice are observed. It is known that AE3-null mice show a greater seizure-induced 
mortality consistent with enhanced neuronal excitability, also NHE1-null mice are 
characterized by increased Na+ currents in hippocampal neurons and, as a 
consequence, by higher excitability resulting in epileptic seizures13,14. Thus, there is a 
reciprocal relationship between neuronal activity and sizable shifts in intracellular 
pH15,16. Given this reciprocal relationship, tools to accurately measure hydrogen ion 
concentration are important for understanding the role that pH plays during the 




1.3 Methods to measure H+ concentration. 
The first method used to monitor intracellular pH changes involved the use of 
pH-sensitive glass electrodes inserted into individual 500-600 µm muscle fibres of the 
crab, Carcinus maenas, for the determination of their intracellular pH17.pH sensitive 
dyes were subsequently developed and, with the discovery of Green Fluorescence 
Protein (GFP), pH sensitive GFP variants were developed. Dyes and engineered GFP 
based pH indicators can be classified into two general families: non-ratiometric and 
ratiometric. Among the non-ratiometric pH sensitive GFP-based probes, the 
“Ecliptic” and “Superecliptic” pHluorins are the most widely employed18,19.These 
GFP variants gradually lose fluorescence as pH is lowered, until at pH values of <6.0, 
the excitation peak at 475 nm vanishes. In an environment of pH <6.0, the protein is 
invisible (eclipsed) under 475-nm excitation but can be seen at 395 nm. These 
changes are reversible within 20 ms after returning to neutral pH18 .Ecliptic and 
superecliptic pHluorins were applied to investigate the exocytosis of presynaptic 
vesicles. Targeted expression of ecliptic and superecliptic pHluorin to acidic 
secretory vesicles allows the real-time analysis of the exocytotic fusion of these 
vesicles to the plasma membrane, as when the pH becomes neutral, there is a 
correspondent increase in fluorescence. pHluorins are thus ideal for the analysis of 
exocytosis, however over time a loss of florescence is observed, due to transit from 
the neutral extracellular environment to an acidic vesicle or to the proteolytic 
breakdown of these tagged proteins in lysosomes, leading to confounding analyses. 
Moreover, the equilibrium between the protonated and deprotonated states of these 
proteins is also affected by temperature and ionic strength. Furthermore, the light 
emitted by such sensor proteins is dependent on their concentration. The latter 
problem was resolved thanks to the introduction of ratiometric pH sensitive dyes and 
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GFP-based probes, which are differentially sensitive to the analytes for at least two 
excitation or emission wavelengths. For instance, for a suitable fluorescent dye, 
emission at one chosen wavelength may be enhanced or diminished relative to the 
emission at another wavelength. The use of ratiometric pH sensors requires 
calibration to characterize the relationship between the fluorescence properties of the 
sensor and pH. The calibration can be carried out adding high K+ buffers at different 
pH together with ionophores such as the K+/H+ exchanger nigericin to equilibrate 
intracellular and extracellular pH. Fluorescence intensities are used to determine 
ratios and by collecting fluorescence ratios at known different pH, a curve can be 
constructed. Interpolating ratio values in this curve, unknown pHi values can be 
extrapolated. The pH-sensitive ratiometric dyes BCECF-AM (2',7'-Bis-(2-
Carboxyethyl)-5-(and-6)-Carboxyfluorescein Acetoxymethyl Ester) and SNARF-AM 
(seminaphtorhodafluor-1-acetoxymethylester) acetoxymethyl ester, are routinely used 
to determine pHi. The presence of a methyl ester makes both dyes membrane-
permeant. Once the dye enters the cell, the methyl ester group is cleaved by 
intracellular esterases, which trap the dyes within cells. The dual-excitation/single-
emission dye BCECF is characterized by a pH-sensitive excitation at 490 nm (λem 535 
nm) and a pH insensitive excitation at 440 nm. The dual-emission dye SNARF has 
pH-sensitive and pH-insensitive emissions at 580 and 640 nm, respectively. The 
ratiometric measurement allows correction for dye leakage out of the cell, 
photobleaching, and differential dye loading between samples. One of the limitations 
of the use of these dyes is that their metabolism, leakage out of the cell, and 
photobleaching will all decrease the fluorescence intensity over time. For this reason, 
dyes are optimally used for short-term measurements. 
The first ratiometric pH sensitive GFP was introduced by Miesenbock and his 
group in 1998. They found that a S202H GFP variant, named pHluorin, displayed a 
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bimodal excitation spectrum with peaks at 395 and 475 nm and an emission 
maximum at 509 nm20 .Upon acidification, pHluorin excitation at 395 nm decreases 
with a corresponding increase in the excitation at 475 nm. Like ratiometric dyes, 
pHluorin is characterized by a pH-sensitive fluorescence with increased intensity at 
higher pH, and by a pH-insensitive fluorescence at the isosbestic excitation at 470 nm 
that can be used to normalize to biosensor abundance. This is different from what 
happens in the ecliptic pHluorin, in which the fluorescence increases with increasing 
pH at 410 nm excitation; however, its emission spectrum does not have an isosbestic 
point to normalize intensity to protein abundance. In 2002, Hanson and collaborators 
constructed a dual emission ratiometric pH sensitive GFP variant called deGFP4. 
This indicator responds to pH changes by opposing changes in blue and green 
emission. At a low pH, excitation of deGFP at 400 nm results in a blue fluorescence 
at 460 nm; at high pH, 400 nm excitation leads to green fluorescence at 516-518 
nm21. As a final example, in 2006 the group of Dr. Bizzarri introduced the ratiometric 
pH sensitive GFP, E2GFP, which contains four mutations with respect to GFPwt: 
F64L/S65T/T203Y/L231H. Thanks to these mutations, E2GFP displays marked 
changes in both excitation and emission fluorescence spectra upon pH variations. 
When excited at 408 nm, E2GFP shows higher fluorescence intensity at acidic pH 
compared to physiological pH, whereas when excited at 473 nm, E2GFP shows the 
opposite behaviour22. These properties make the E2GFP suitable to study the 
extracellular pH shifts during epileptic like conditions. Using this tool, Chiacchiaretta 
and colleagues demonstrated that, upon induction of neuronal hyperexcitability by 
convulsant drugs or high frequency electrical stimulation, extracellular acidification 
occurs at cell bodies and at synapses due to the activation of NHE123. Recently, 
ratiometric GFP based probes were used by Raimondo and colleagues24 to investigate 
the possibility for genetically encoded pH reporters to measure neuronal intracellular 
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pH transients associated with periods of elevated activity. The intracellular pH of 
individual pyramidal neurons within the CA1 and CA3 regions was measured using 
E2GFP22 and deGFP421. Both pH sensors were able to report acidic shifts associated 
with epileptiform activity. 
 
1.4 Seizures and epilepsy. 
As said in previous paragraphs, a dysregulation of extra-intracellular pH 
homeostasis can induce pathological states like seizures and epilepsy. Seizures are 
temporary disruptions of brain function resulting from abnormal, excessive neuronal 
activity; epilepsy is a chronic condition of repeated seizures. Seizures can be 
classified in generalized and focal (or partial). A generalized seizure involves both 
hemispheres from the onset. Focal seizures originate instead in a small group of 
neurons, the seizure focus, which has enhanced excitability and the ability to spread 
that to other regions and cause a seizure. 
How does enhanced excitability spread beyond the seizure focus? Each neuron 
in a seizure focus is characterized by sustained depolarization resulting in bursts of 
action potentials, followed by a rapid repolarization and hyperpolarization. This event 
is called paroxysmal depolarizing shift. The first depolarization phase depends 
primarily on the activation of AMPA and NMDA-type receptor channels and on the 
influx of extracellular Ca2+, which leads to the opening of voltage-dependent Na+ 
channels, influx of Na+, and generation of repetitive action potentials. The NMDA-
type channels are able to enhance excitability because depolarization allows the 
removal of the Mg2+ blockage of the channel. Once unblocked, the excitatory current 
through the channel increases, enhancing the depolarization and allowing extra Ca2+ 
to enter the neuron. The subsequent hyperpolarizing afterpotential is mediated by 
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GABA receptors and Cl− influx, or by K+ efflux. Hyperpolarization is important 
because it limits the duration of paroxysmal depolarizing shift. As long as the 
enhanced electrical activity is restricted within the focus there are no clinical 
manifestations. Usually, the abnormal activity is confined in a small group of neurons 
thanks to inhibitory effects of the excited region on surrounding tissue26. This 
inhibitory surround is dependent on the inhibition activity of GABAergic inhibitory 
interneurons. During a focal seizure, the inhibitory surround is overcome and the final 
hyperpolarization phase in the neurons of the focus disappears. The result is the 
spread of the seizure beyond the focus and the generation of continuous high 
frequency train of action potentials.  
A very important factor in the spread of focal seizures is not only an increase of 
glutamatergic drive, but also a change in GABAergic effect. It is reported that an 
increase in postsynaptic chloride occur causing the shift of EGABA to depolarizing 
levels. When the failure of the restraint period occur, the chloride loading is high 
because the membrane potential is shifted away from the resting EGABA for the 
concurrent glutamatergic drive causing a larger GABAergic current25. 
An intense neuronal firing causes also the increase of extracellular levels of K+ 
contributing to an increase of chloride loading because chloride clearance occurs 
through the KCC2 transporter that is controlled by the K+ electrochemical gradient. A 
reduction of K+ electrochemical gradient modifies the clearance of chloride26 . 
 
1.5 Animal models to study epilepsy and epileptic seizures. 
In the world, the incidence of epilepsy is about the 1% of total population and 
the 30% of patients do not respond to conventional drug treatments. For this reason, 
several experimental animal models of epilepsy have been developed in which the 
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epileptic phenotype is simulated and different treatments are tested. These models are 
instrumental in the search for similarities with the mechanisms of human epilepsy. 
Animal models are subdivided in genetic and acquired, and the latter further 
subdivided into electrical or chemical induced27. Genetic animal models include 
animals with spontaneous or induced mutations resulting in recurrent seizures. For 
example, mutations in GluA4 AMPARs have been causally linked to absence 
seizures28. Electrical models like kindling are instead based on gradual development 
of seizures after repeated stimulation in initially healthy animals. In chemical 
induction models, pro-convulsants such as pentylenetrazol, kainic acid or bicuculline 
are injected into an animal to induce chronic seizures27 or can be injected at high 
doses (for instance, pentylenetrazol injection) to reproduce acute seizures. These 
chemicals act on receptors critically involved in synaptic transmission, thereby 
disturbing the excitatory-inhibitory balance, enhancing excitation or blocking 
inhibition, and resulting in seizures. Chemical convulsants can be administered either 
intracerebrally or systemically. 
Kainic acid (KA) is a cyclic analogue of L-glutamate and an agonist of 
ionotropic KA receptors. KA induces progressive limbic seizures mimicking human 
temporal lobe epilepsy (TLE). TLE symptoms consist of focal seizures that originate 
in the hippocampus, entorhinal cortex or amygdala many years after a brain injury 
like status epilepticus, encephalitis of febrile convulsions. Patients with TLE typically 
show hippocampal sclerosis with neuronal loss (for instance GABAergic 
interneurons) in the CA1/CA3 region of the hippocampus and the hilus, along with 
granule cell dispersion and aberrant mossy fiber sprouting in the molecular layer of 
the dentate gyrus. The hippocampus is indeed one brain region highly susceptible to 
neuropathological changes after either local or systemic administration of KA29. 
Intraventricular administration of KA preferentially damages the CA3 and CA4 
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regions of the hippocampus but leaves the CA1 region and the dentate gyrus almost 
intact. Intrahippocampal administration of KA produces CA3 pyramidal cell loss 
even if the injection is performed in distal regions such as CA1. Spontaneous seizures 
develop between 5 days to one month after the administration of KA in the 
hippocampus30,. The pentylentetrazol (PTZ) model of epilepsy is considered similar 
to primary tonic-clonic generalized epilepsy in humans. PTZ is a GABAA receptor 
antagonist that produces severe convulsions when administered to animals. It 
mediates a loss of inhibition induced by GABA by specifically blocking GABAA 
receptors, as bicuculline is a competitive antagonist of GABAA receptors
31. As an 
antagonist of the action of GABA neurotransmitter, bicuculline produces acute 
focused epileptic convulsions when administered systemically or when applied 
locally into the cortex. Bicuculline effects are evident within 1–5 min32. 
 
1.6 Possible options to treat seizures and epilepsy. 
Therapies to treat epilepsy are available. In many cases, patients with epilepsy 
can lead a normal life thanks to antiepileptic drugs (AEDs). Many anticonvulsant 
drugs act by blocking excitation or enhancing inhibition. For example, 
benzodiazepines like diazepam and lorazepam enhance GABAA-mediated inhibition, 
phenytoin and carbamazepine cause reduction in the opening of voltage gated Na+ 
channels. However, despite progress in drug and epilepsy research, about 35% of all 
epileptic patients show recurrent spontaneous seizures that are refractory to AED 
administration. Drug resistance is a problem especially in patients with temporal lobe 
epilepsy, where seizures originate from the temporal lobe, mostly from the 
hippocampus, as said in the previous paragraph. Unfortunately, other treatment 
possibilities for drug resistant patients are limited. The ketogenic diet is a possibility 
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whose efficacy is however limited to some types of infantile epilepsies. Surgical 
intervention is another possibility and consists in the surgical resection of the seizure 
focus. For instance, amygdalohippocampectomy is usually performed for TLE. 
Unfortunately, a limited number of epilepsies are curable through surgery. Finally, 
another possible treatment is brain stimulation. Vagus nerve stimulation (VNS) is the 
most commonly used. In this procedure, a prosthesis is implanted under the skin of 
the patient chest. The stimulating electrodes carry intermittent electrical currents from 
the generator to the vagus nerve. The mechanism of action of VNS is not completely 
understood. It is possible that the activation of brain steam nuclei is involved, with 
projections in limbic, reticular and autonomic regions of the brain, the main targets of 
vagal afferents. In this context, the immunomodulatory function of the vagus nerve is 
very interesting. Afferent signals can activate the so-called cholinergic anti-
inflammatory pathway upon inflammation. Through this pathway, efferent vagus 
nerve fibers inhibit the release of pro-inflammatory cytokines and in this way reduce 
inflammation, which plays an important role in seizures and epilepsy33. 
Despite important advancements, however, refractory epilepsies still represent a 
serious problem. For this reason, novel possible approaches for epilepsy treatment are 
being investigated, amongst them gene therapy. Gene therapy in the nervous system 
involves the transfer and expression of genes into brain tissue, which is possible 
thanks to the use of viral vectors like lenti-virus, adeno-associated virus (AAV), and 
herpes simplex virus (HSV) that allow long term gene expression without notable 
toxicity. The expression of therapeutic genes can be targeted to a specific cell type 
using specific promoters, specific virus serotypes or choosing a precise injection site. 
For epilepsy treatment, gene therapy can act through several mechanisms. For 
instance, it can modulate hyperexcitability by transduction of endogenous cells and 
expression of inhibitory modulators. One of the first therapeutic examples of using 
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viral vectors to constrain seizures was based on the bioactive neuropeptide galanin. 
Galanin is a 29-30 amino acid peptide highly distributed in the brain, especially in the 
septum and in locus coeruleus. The axons of the neurons located in these structures 
project to the hippocampus where the density of galanin receptors is high34. 
Physiological studies suggest that galanin has an inhibitory action in the hippocampus 
because it inhibits excitatory post-synaptic potentials (EPSPs) in pyramidal neurons 
of CA135. For this reason galanin may have a modulatory effect on seizures. In some 
studies, AAV-mediated galanin overexpression suppressed intrahippocampal and 
intraperitoneal KA-induced seizures36. Another gene therapy-based strategy has been 
to decrease seizure-induced hyperexcitability by the expression of proteins called 
opsins to silence neuronal firing in excitatory cells or to induce firing in inhibitory 
cells. The use of opsins to modulate neuronal activity is the principle on which 
optogenetics is based. 
 
1.7 A new way to modulate neuronal activity: optogenetics. 
In recent years, a new technology called “optogenetics” has been introduced, 
which is based on the combination of optics and genetics. After the delivery of light 
sensitive opsin genes such as channelrhodopsin-2 (ChR2), halorhodopsin (NpHR) 
and others into the brain, excitation or inhibition of specific neurons in precise brain 
areas can be controlled by illumination at different wavelengths with very high 
temporal and spatial resolution. The development of such a revolutionary technique is 
due to the work of different research groups. For the first time Miesenbock and his 
group in 2002 developed the possibility to sensitize non-photoreceptor cells to light 
introducing in cultured mammalian neurons a combination of three proteins derived 
from Drosophila melanogaster. By using this system, called “chARGe”, it was 
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possible to control the activity of cultured mammalian neurons37. Only after the 
discovery of Channelrhodopsin-2 (ChR2) from the algae, Clamydomonas reinhardt 
and Halorhodopsin (NpHR) from Natromonas Pharaonis, E. Boyden and K. 
Deisseroth developed the possibility to induce respectively the activation and the 
inhibition of neuronal activity with light38,39. When activated by a series of brief 
pulses of blue light, ChR2 channels open and allow the passive movement of Na+, K+, 
Ca2+ and H+ following the electrochemical gradient40. Such ion flux leads to the net 
depolarization of the neuronal membrane, and if the cell is depolarized to threshold, 
action potentials are generated with millisecond timescale temporal resolution 
(Boyden et al., 2005). Instead, after illumination with green/yellow light, NpHR 
pumps Cl- ions inside the cells mediating the inhibition of spike trains with high 
stability39 . 
The great advantage of optogenetics is the possibility to achieve cell-type 
specificity. Different cell types can be distinguished thanks to well-defined promoter 
activities. In this way, it is possible to target specific populations when they are 
interspersed among numerous other neuronal and non-neuronal cell types, for 
instance glial or endothelial cells. Another big advantage of optogenetics is the 
possibility of obtaining bidirectional control, as targeted neurons can be silenced or 
activated via different optogenetic probes. One disadvantage is linked to the 
illumination procedure. It is not possible to activate all brain cells at a given time 
point due to the limitations in the tissue volumes that can be illuminated at sufficient 
intensity. Only cells transduced and illuminated in a given tissue volume will be 
photosensitive, while cells that are not transduced or not sufficiently illuminated will 
be not photosensitive. 
The potential to use optogenetics as therapeutic tool has been investigated since 
its early development. For example, optogenetics has been used to treat 
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neurodegenerative disorders, such as Parkinson’s disease41, as well as to treat non-
neurological conditions such as ventricular tachycardia or ventricular fibrillation42. 
However, among the neurological disorders in which optogenetics can be applied, 
epilepsy is the best candidate. In epilepsy treatment, two optogenetics-mediated 
seizure-suppressant strategies can be used: silencing of endogenous excitatory cells, 
or activating endogenous GABAergic interneurons. Alternatively, these approaches 
can be combined and applied simultaneously and, alone or together, these strategies 
may normalize hyperexcitability in the epileptic foci in the brain. 
 
1.8 Epileptic seizures control through optogenetics. 
The activation of inhibitory interneurons involves the selective expression of 
ChR2 in GABAergic interneurons, which will mediate their activation upon blue light 
stimulation. This strategy was used to control a mixed population of interneurons by 
vesicular GABA transporter (VGAT) promoter-mediated ChR2 expression, and also 
to control fast-spiking interneurons by using parvalbumin (PV) promoter-driven 
ChR2 expression43. However, the effect of ChR2 can ‘backfire’ because the enhanced 
GABA release in some circumstances may increase synchronization of the network 
activity, and promote seizures44. Moreover, in some focal epilepsies like TLE a loss 
of interneurons is observed, which may reduce the effectiveness of this optogenetic 
approach. 
The best way to shut down the excessive excitation that occurs during epileptic 
seizures is to induce the silencing of hyperexcited neurons. This strategy is possible 
thanks to the specific expression of the chloride pump Natromonas Pharaonis 
Halorhodopsin (NpHR)45 in pyramidal neurons. The expression in this cell type can 
be mediated by a specific promoter like the Ca2+/calmodulin-dependent protein kinase 
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II ɑ (CaMKIIɑ). The photocycle kinetics of NpHR is on the millisecond scale, which 
allows fast neuronal inhibition resulting from hundreds of pA currents, readily 
translating into tens of mV hyperpolarization. Recently, in order to increase the rate 
of NpHR-mediated hyperpolarization, some groups worked to improve the 
halorhodopsin trafficking to the plasma membrane and to increase the export from the 
ER. For these purposes, an ER export sequence and a trafficking signal from the 
inward rectifying K+ channel 2.1 (Kir2.1) were inserted at the C-terminal of the 
fusion protein. These modifications improved the surface membrane expression and 
photocurrents were profoundly increased in response to green/yellow light 
illumination. The new halorhodopsin variant was called eNpHR3.0 45. Tønnesen and 
colleagues used eNpHR to hyperpolarize hyperexcited neurons in an in vitro model of 
epilepsy based on stimulation train-induced bursting in mouse hippocampal 
organotypic cultures, which in several ways is similar to pharmacoresistant human 
tissue from TLE patients. In these experiments eNpHR was specifically expressed in 
excitatory hippocampal neurons by introducing it in a lentiviral vector under the 
CaMKIIα promoter, which was injected directly into the hippocampus. This study 
demonstrated that the eNpHR expressed in hippocampal neurons, upon activation 
with yellow light, is capable of blocking epileptiform activity46. Another group used 
the halorhodopsin approach to study the in vivo suppression of epileptiform activity 
in the KA model of TLE. After light stimulation of precise neuron populations 
expressing NpHR, significant seizure control was achieved, stopping electrographic 




1.9 Can optogenetics be applied in humans? 
The different approaches for epilepsy treatment previously described require 
invasive brain surgery that is the only route of administration approved. This aspect 
can be a problem and the search for new ways of administration is a challenge. 
However, another aspect is to be taken in consideration. The very important concept 
at the basis of the optogenetic approach is the precise spatiotemporal wavelength-
specific illumination. Despite poor light penetration in the brain tissue, implantable 
laser-coupled optical fibers or head mounted light emitting diodes (LEDs) are used 
for the delivery of light to the surface of the brain in awake and mobile animals. In 
humans, the situation will be different because of the larger brain areas to be 
illuminated. Conceivable strategies could be the construction of bundled optical fibers 
that branch out from the site of implantation or allow photons to escape from the side 
where the optical fiber is located. In these ways, the illumination volume is 
enlarged48. Recently, a multi electrode array coupled with an optical fiber has been 
constructed. This so called “optrode-MEA” device is able to deliver light to neural 
tissue and in the same time to record multisite extracellular activities from an area of 
4.0 mm × 4.0 mm around the stimulation focus49. An upgrade of the “optrode-MEA” 
was developed in 2012. This new device is able to deliver optical excitation to a 
single cortical site while mapping the neural response from the surrounding 30 
channels of the 6 × 6 element MEA for 8 month in chronically implanted ChR2 
expressing rats50. The size of the last device is similar to the one used for the deep 
brain stimulation in clinical settings for patients, so it could be used in patients in any 
region of the brain enabling the illumination of larger brain areas. Although the 
development of strategies to enable optical fiber-mediated illumination of larger brain 
areas, chronically implanted optical fibers pose risks for infection and tissue damage. 
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Moreover, the transmission of external light through the brain is inefficient because 
of light scattering and tissue absorption. In fact, most of the light emitted by optical 
fibers is attenuated within 1 mm from the fiber tip51. 
In the last years, one potential solution to this issue has been addressed, i.e. to 
eliminate the need for an external light source by creating a system in which the 
animal produces its own light. The production of light in this case is due to the action 
of light-producing proteins that exist in nature, named luciferases. These proteins can 
be expressed using viral systems in a way similar to the opsins, to internally generate 
light after the reaction with a specific substrate. In recent years, bioluminescence was 
applied in many molecular imaging applications in alternative to fluorescence 
imaging. In fluorescence imaging, photobleaching decreases signals over time while 
phototoxicity leads to damaged or dead cells due to light-induced generation of free 
radicals52. Both these phenomena are non-existent in bioluminescence. These features 
make the bioluminescence a potentially good tool for light delivery in optogenetics 
applications. 
 
1.10 Bioluminescence and optogenetics. 
In a bioluminescence-based optogenetic system, light is generated by the 
luciferase to activate the opsin, resulting in the activation (in case of 
channelrhodopsins) or inhibition (in case of proton or chloride pumps) of the target 
neurons. For the first time Berglund and colleagues managed to activate ChR2 using 
the Gaussia Luciferase (GLuc) light. In this case ChR2 could be activated directly by 
illumination, but also chemically by the luciferase substrate, coelenterazine. 
Coelenterazine is oxidized by GLuc to generate bioluminescence that peaks at 470 
nm, which matches the excitation spectrum of ChR253. Other groups tried to use a 
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combination of opsins and luciferases to modulate neuronal activity. For example 
Land et al. used the Firefly luciferase (FLuc) in combination with NpHR in order to 
obtain the inhibition of neuronal activity. FLuc produces yellow-red light in the 
presence of its substrate, luciferin54. Notably, the emission spectrum of firefly 
luciferase overlaps highly with the action spectrum of NpHR. This suggests that with 
sufficient light output, luciferase could serve as a light source that would activate 
halorhodopsin and inhibit neural activity, eliminating the need for an external light 
source55. However, the bioluminescent signal is 103 times lower than the fluorescent 
signal52 and the light output from luciferases is insufficient to provide temporal and 
spatial resolution equivalent to fluorescence so when it is applied to optogenetics, the 
hyperpolarization/depolarization rate is low. The problem of low brightness has been 
solved in nature by the phenomenon of bioluminescence resonance energy transfer 
(BRET), in which the emitted light coming from the reaction of the luciferase with its 
specific substrate excites a fluorescent protein increasing the number of emitted 
photons. There are many types of luciferases, such as the above-mentioned Firefly 
and Gaussia Luciferase, but the luciferase utilized as a BRET donor is mainly Renilla 
luciferase (RLuc). Renilla luciferase is the most used because it is not ATP dependent 
and in general requires only molecular oxygen in addition to its substrate, the 
coelenterazine (CTZ), for luminescence. The limiting factors of RLuc reaction are its 
rapid inactivation and low brightness. To improve RLuc characteristics, site directed 
mutagenesis of the RLuc gene and chemical synthesis of analogues of the 
coelenterazine were performed56,57 .Combining RLuc variants and coelenterazine 
analogues, a variation of the wavelength of RLuc emission spectrum is also possible. 
This last aspect is very important in BRET, in order to obtain different donor 
emission spectra for the excitation of various fluorescent proteins. The first RLuc 
variant, obtained by Loening et al., was called RLuc8. It presented eight mutations 
22 
 
(A55T, C124A, S130A, K136R, A143M, M185V, M253L, and S287L) and exhibited 
a 200-fold improvement in resistance to murine serum inactivation at 37°C, a 4-fold 
improvement in light output, and a 5-nm red shift in the emission spectrum in 
comparison with the native RLuc. However for imaging bioluminescent reporters in 
animals, RLuc variants with an emission from red to near infrared wavelength were 
needed. Thus, several red shifted variants were obtained by random mutagenesis of 
luciferase proteins and upon the reaction with coelenterazine analogues. Mutants with 
maxima in the yellow and yellow-orange region were obtained, characterized by high 
stability and brightness56. As said before, chemical synthesis of coelenterazine 
analogues was performed for the optimization of RLuc emission. During the 70s 
several coelenterazine analogues were synthesized, including coelenterazine h and 
coelenterazine 400a58. Coelenterazine h, when reacting with RLuc emits light at a 
wavelength of 470-480 nm with a 10 to 20 fold higher luminescent intensity of that of 
native coelenterazine. Coelenterazine 400a is very used in BRET studies because it 
emits at 390 - 400 nm that has minimal overlapping with the emission of the GFP 
acceptor. Over the years, more coelenterazine variants have been modified in order to 
obtain a better stability and a controlled reaction with the enzyme [Figure 1]. 
 
Figure 1. Bioluminescence of Rluc variants in the presence of coelenterazine 400a, native 




Thanks to the optimization of the various luciferases and substrates, the BRET 
mechanism can now be used efficiently in optogenetic. Recently, Tung et al. 
bypassed the use of an external light source to activate the inhibitory opsin 
eNpHR3.0. They coupled NpHR to a bioluminescent light source, a luciferase, 
exploiting the BRET mechanism. The resulting construct was named ILMO251 
[Figure 2A]. ILMO2 is a fusion protein composed of eNpHR3.0 and a construct 
called “Nanolantern”, which is composed of a variant of RLuc, Rluc8 (S257G) fused 
to a variant of YFP, Venus [Figure 2B]. The function of Nanolantern is based on the 
BRET mechanism52. To optimize the BRET efficiency and the brightness of 
Nanolantern, Saito et al. constructed a protein chimera composed of a Venus protein 
truncated at the C terminal of 10 amino acids, and an Rluc8-S257G truncated at N 
terminal of 3 amino acids, linked by 3 amino acids. Rluc8(S257G) is activated by 
reaction with its specific substrate, coelenterazine h, with an emission spectrum at ~ 
480 nm. ILMO2 was later shown to be functional to treat pathological conditions. It 
is able to suppress seizure activity after the focal injection of bicuculline methiodide 
in the hippocampus of anesthetized rats. Moreover, ILMO2 is most likely able to 
achieve a higher degree of suppression compared to the fiber-based illumination 
method because a larger volume of tissue is influenced, which is determined by the 
extent of iLMO2 expression rather than by light transmittance of an optical fiber59. 
 
Figure 2. Schematic representation of the ILMO2 fusion protein (A)51and of the Nanolantern 
fusion protein (B)52. 
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2. Aim of the thesis 
The purpose of this work is to develop a new strategy to reduce neuronal 
hyperexcitability, with the aim of devising novel therapeutic approaches to ameliorate 
the epileptic phenotype. To this aim, we engineered a new probe, pHIL, which takes 
advantage of chemogenetics, optogenetics and of the intracellular acidification that 
occurs during epileptic conditions to reduce the neuronal hyperexcitability state. 
pHIL is composed of eNpHR3.0, a chloride pump that inhibits neuronal firing when 
activated by green/yellow light, E2GFP, a ratiometric pH sensitive variant of GFP, 
and RLuc8(S257G), a mutant of Renilla luciferase whose emission is blue-shifted 
upon reaction with CTZ 400a, a specific coelenterazine variant. When the 
intracellular pH decreases, such as during epileptic conditions, and upon the addition 
of CTZ 400a, the probe is activated. The light cascade starts with the emission of 
near-UV light (≈ 405 nm) from RLuc8(S257G). This light will activate E2GFP 
selectively under acidic conditions. E2GFP will in turn emit 510 nm light that will 
activate NpHR3.0, ultimately inhibiting neuronal firing. 
 Our first aim was to engineer the active and control probes through molecular 
cloning. Five different constructs were cloned, two for the characterization of 
the probe in HEK293T cells and three for AAV2.9 production and the 
subsequent characterization of the probe in primary neurons and in vivo. 
 We then studied the expression and localization of the probes in HEK293T 
cells using immunofluorescence and western blot techniques, and 
characterized the light cascade taking advantage of the BRET in vitro 
detection assay. We also characterized the function of the probe using patch 
clamp recordings, analyzing the changing in HEK293T membrane potential 
upon addition of CTZ400 a.  
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 Finally, we started the characterization of pHIL in primary hippocampal 
neurons analyzing its localization and expression. In parallel, we studied 
neuronal intracellular acidification in an in vitro model of epilepsy through 
live cell imaging. We also performed functional studies on pHIL expressing 




3. Materials and methods 
3.1 Cloning strategies 
a. pHIL and control plasmids 
All restriction enzymes were from Promega (Madison, Wisconsin) unless 
otherwise indicated; all the final plasmids were verified by direct sequencing. All 
constructs were initially cloned in the pcDNA3.1 plasmid under the control of the 
cytomegalovirus (CMV) promoter. The eNpHR3.0 and the ΔN3-RLUC8-S257G 
sequences were amplified from the plenti-ILMO2 and pAAV2-ILMO2 constructs (a 
gift of Dr. Gross, Emory University, Atlanta, Georgia, USA), respectively. The 
truncated form of E2GFP (ΔN12-E2GFP-ΔC15) was amplified from pcDNA-E2GFP 
(a gift of Dr. Bizzarri, NEST CNR-INFM, Scuola Normale Superiore, Pisa, Italy). 
- To obtain the Ctrl construct, the ΔN3-RLUC8-S257G sequence was PCR 
amplified using the Pfu DNA Polymerase (BiotechRabbit, Berlin, Germany 
#BR0300101) and the following primers: 
Fw: 5’-ATCCggtaccaaggtgtacgaccccgag-3’ 
Rv: 5’-ATCCgaattcttacacctcgttctcgtagc-3’ 
Both pcDNA3.1 and ΔN3-RLUC8-S257G were subsequently digested with the 
ECORI/KPNI restriction enzymes and ligated using T4 ligase. 
The ΔN12-E2GFP-ΔC15 sequence was PCR amplified using the Pfu DNA 
polymerase and the following primers: 
Fw: 5’-ATCCaagcttagggatccatggtgagcaagggcgaggagctg-3’ 
Rv: 5’- ATCCggtacccccggcggcggtcacgaac-3’  
Both ΔN12-E2GFP-ΔC15 and pcDNA-ΔN3-RLUC8-S257G were digested with 
the HINDIII/KPNI restriction enzymes and then ligated to insert ΔN12-E2GFP-








- To obtain the pHIL construct, eNpHR3.0 was PCR amplified using the Pfu 
DNA polymerase and the following primers: 
Fw: 5’-ATCCggatccatgacagagaccctgcctcccG-3’ 
Rv: 5’-ATCCgcggccgcatcatcagccggggtc-3’ 
Both pcDNA3.1 and eNpHR3.0 were subsequently digested with the 
BAMHI/NOTI restriction enzymes and ligated using T4 ligase. 
The ΔN12-E2GFP-ΔC15 – ΔN3-RLUC8-S257G sequence was PCR amplified 
from the Ctrl plasmid using the Pfu DNA polymerase and the following 
primers: 
Fw: 5’- ATCCgcggccgcaGTGAGCAAGGGCGAGGAGCTG-3’ 
Rv: 5’-ATCC CTCGAG gaattcttacacctcgttctcgtagc-3’ 
Both pcDNA-eNpHR3.0 and the ΔN12-E2GFP-ΔC15 – ΔN3-RLUC8-S257G 
sequence were digested with the NOTI/XHOI restriction enzymes and ligated, 
to insert the ΔN12-E2GFP-ΔC15 – ΔN3-RLUC8-S257G sequence downstream 









Both constructs also included an ER-export sequence (from pLenti-ILMO2) at 
the 3′ end of the fusion protein. The ER export sequence is a sorting signal that 
facilitates the ER export of proteins and their insertion in plasma membrane 
(Gradinaru et al.,2014). 
The pHIL and Ctrl cassettes were subsequently cloned into the pAAV2 
backbone (from pAAV2-ILMO2) for production of AAV2/9-pHIL and 
AAV2/9-ctrl. To achieve this, the pAAV2 backbone (pAAV2-ILMO2)  , 
pcDNA-pHIL and pcDNA- Ctrl plasmids were digested with BAMHI/ECORI 
restriction enzymes and then ligated. To reduce the total plasmid length, in 
order to allow the production of AAV particles, the CaMKIIɑ (1.3 Kb) 
promoter was substituted with the CaMKIIɑ mini (0.3 Kb) promoter.  
For the cloning of pAAV2- pHIL , the CaMKIIɑ mini (0.3 Kb) promoter was 
amplified from the pAAV2- ILMO2 plasmid using the Pfu DNA polymerase 
and the following primers: 
Fw: 5’ATCCacgcgtacttgtggactaagtttgtt-3’ 
Rv: 5’-ATCCggatccgctgcccccagaactagggg-3’ 
Both CaMKIIɑ mini (0.3 Kb) promoter and the recipient vector (pAAV2-pHIL) 
were digested with the MLUI/BAMHI restriction enzymes and then ligated 
(Figure 5B). 
For the cloning of pAAV2-ctrl , the CaMKIIɑ mini (0.3 Kb) promoter and the 
ΔN12-E2GFP-ΔC15 – ΔN3-RLUC8-S257G sequence were PCR amplified from 
the pAAV2-pHIL ctrl (containing the CaMKIIɑ (1.3 Kb) promoter) using the 





Both CaMKIIɑ mini (0.3 Kb) - ΔN12-E2GFP-ΔC15 – ΔN3-RLUC8-S257G 
sequence  and the recipient vector (pAAV2-ctrl) were digested with the 





Figure 5. Schematic representation of the cloning strategy used to engineer the AAV2-pHIL (B) 
and the AAV2- ctrl (A) constructs with the mini CaMKIIɑ (0,3 Kb) promoter. 
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b. CD4 – ΔN12-E2GFP-ΔC15 
The truncated form of the E2GFP (ΔN12 E2GFP-ΔC15) was cloned in the 
hCD4-mOrange plasmid (#110192, Addgene, Watertown, Massachusetts, USA) 
downstream of the CD4 sequence. First, an ER export sequence was inserted 
downstream of truncated E2GFP by PCR amplification using the following primers: 
Fw: 5’-ATCCaagcttatggtgagcaagggcgaggagctg-3’ 
Rv: 5’-ATCCgtagcagaacccggcggcggtcac-3’ 
For the second PCR amplification, the ΔN12 E2GFP-ΔC15/ER was used as template 
for a second PCR reaction using the following primers: 
Fw: 5’-ATCCaagcttatggtgagcaagggcgaggagctg-3’ 
Rv: 5’-ATCCgaattcttacacctcgttctcgtagcagaa-3’ 
The amplified sequence and the hCD4-mOrange plasmid were digested with the 
HINDIII/ECORI restriction enzymes and then ligated [Figure 6A]. 
The CD4-ΔN12 E2GFP-ΔC15/ER sequence was subsequently cloned in the lentiviral 
backbone plenti-Ub-iLMO2 (a gift of Dr. Gross), downstream of the ubiquitous 
promoter of human ubiquitin (hUb). CD4-ΔN12-E2GFP-ΔC15/ER was PCR 
amplified using the following primers: 
Fw: 5’-ATCCggatccatgaaccggggagtccc-3’ 
Rv: 5’-ATCCGaattcttacacctcgttctcgtagcagaa-3’ 
Both plenti-Ub-iLMO2 and the amplified sequence were digested with the 










































Figure 6. Schematic representation of the cloning strategy used to engineer the pLenti-hCD4- 
ΔN12 E2GFP-ΔC15 construct. 
 
After the cloning, the correct expected length of each construct was analyzed through 
renstriction enzymes digestion. Digestion products were, then, analyzed using agarose 






3.2 Cell cultures, transfection and infection 
All cell culture reagents were from Invitrogen (Carlsbad, California,), unless 
otherwise specified. 
Human embryonic kidney (HEK) 293 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen #11995-073) supplemented with 10% 
fetal bovine serum (FBS), 1% glutamine and 1% Penicillin/Streptomycin (complete 
DMEM), in a humidified 5% CO2 atmosphere at 37 °C. For splitting, cells were 
carefully washed with PBS and incubated with trypsin/EDTA for 1-2 min. Cells were 
subsequently centrifuged at 1000 rpm for 5 min, and then resuspended in fresh 
medium. 
Hippocampal neurons were obtained from embryonic day (E)18.5 C57BL6/J 
mouse embryos. Hippocampi were dissected in ice-cold PBS, incubated with trypsin 
0.125% for 15 min at 37 °C, and mechanically dissociated. Neurons were then 
resuspended and plated on poly-D-lysine-coated glass coverslips or plastic wells in 
Neurobasal medium containing 10% Fetal Bovine Serum (FBS), 1% glutamax and 
1% Penicillin/Streptomycin. After 3 h, the medium was removed and replaced with 
neurobasal containing 2% B27 supplement, 1% glutamax (a dipeptide, L-alanine-L-
glutamine, which is more stable in aqueous solutions) and 1% 
Penicillin/Streptomycin. 
HEK293 cells and hippocampal primary neurons were transfected with using 
Lipofectamine 2000 following manufacturer’s recommended protocols. 
Hippocampal neurons were infected at DIV 3 with AAV2/9 CaMKIIɑ(0.3)-
pHIL and with AAV2/9 CaMKIIɑ(0.3)-Ctrl following standard procedures (viruses 
were produced by TIGEM AAV vector core facility at a title of 1012 GC/ml). 




3.3 Immunofluorescence staining and confocal analysis 
HEK293T cells and hippocampal neurons were plated on poly-D-lysine-coated 
18 mm coverslips. 48 h after HEK293T cell transfection, cells were incubated with 
CellMask deep red (#C10046, Termofisher Scientific, Waltham, MA USA) an 
amphipathic molecule formed by a lipophilic moiety for membrane loading and 
a negatively charged hydrophilic dye to anchor the probe in plasma membrane. 
HEK293T cells were incubated with the probe for 5 minutes, washed with PBS 1x 
and analyzed for plasma membrane staining in live imaging using the Leica SP8 
confocal microscope.  
7 days after hippocampal neurons infection, samples fixed with PBS / 4% 
paraformaldehyde for 20 min and subsequently permeabilized for 5 min with PBS / 
0.2% Triton X-100 and then incubated in blocking buffer (PBS / Tween 0.05% / 3% 
BSA) for 30 min. Cells were then incubated for 1 h at RT with primary antibodies 
(rabbit polyclonal anti-GFP, #A111222 Life Technologies, 1:200) diluted in blocking 
buffer, carefully washed and incubated for 45 min RT with secondary antibodies 
(Alexa Fluor® 488 anti rabbit, # A32790 Life Technologies, 1:500) diluted in 
blocking buffer. Coverslips were then mounted using ProLong antifade (#P36931, 
Life Technologies) and imaged using a Leica SP8 confocal microscope (Leica 
Mycrosistems, Wetzlar, Germany) with a 63X oil-immersion objective. 
 
3.4 Protein extraction and western blotting 
HEK293T cells and hippocampal neurons were lysed using RIPA buffer [0.5 
mM EDTA, 20 mM Tris HCl pH 8, 100 mM NaCl, 0.5 % Np40, 0.5% Na-
deoxycholate, protease inhibitor cocktail (#04693116001, Roche Applied Science, 
Penzberg, Germany), phosphatase inhibitor cocktail 2 (#P5726, Sigma, St. Louis, 
Missouri, USA) and phosphatase inhibitor cocktail 3 (#P0044, Sigma)]. The final 
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protein concentration was quantified using the BCA protein assay kit (#23225, Pierce 
Biotech, Waltham, Massachusetts, USA). 
Proteins were separated on the basis of their molecular weight through sodium 
dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently 
transferred to a nitrocellulose membrane, following standard protocols. Membranes 
were incubated in blocking buffer (1X TBST / 5% w/v nonfat dry milk) for 1 h and 
then incubated with primary antibodies diluted in blocking buffer for 1 h (antibodies 
used are summarized in the Table 1.). Membranes were then washed several times in 
TBST incubated with secondary antibodies (goat anti-rabbit IgG (H+L), Peroxidase 
Conjugated, #PR31460, Life technologies) for 45 min and revealed using ECL™ 
Blotting Reagents (#RPN2109, GE Healthcare, Chicago, Illinois, USA). 
 
Antibody Source Cat.Number Diluition Company 





Rabbit ab185926 1:1000 
Abcam 
(Cambridge,UK)  
ɑ- Actin Rabbit A2066 1:5000 
Sigma-Aldritch 
(St.Louis, USA) 
GAPDH Rabbit 14C10 1:10000 
Cell Signaling 
(Danvers, USA) 
Table 1. Primary antibodies used for western blot analysis. 
 
3.5 Coelenterazine preparation 
Coelenterazine 400a (CTZ 400a) was purchased from Santa Cruz 
Biotechnology (Dallas, Texas, USA) (#sc-280647) and solubilized in Ethanol 100% 
at 1 mM following manufacturer’s recommended protocol. Before every experiment, 
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the stock solution was diluted in 20 mM (2-Hydroxypropyl)-β-cyclodextrin (Sigma, 
#H5784) to the required concentration (5, 10, 20, 40, 50 µM) and added to the 
external recording solution. Coelenterazine-h (CTZ h) (Promega, #S2011) was 
solubilized in 20 mM (2-Hydroxypropyl)-β-cyclodextrin in PBS as described by Dr 
Osamu Shimomura57 and used at the final concentration of 20 µM51. Frozen stock 
solutions were kept at -20°C and protected from light. 
  
3.6 Bioluminescence Resonance Energy Transfer (BRET) in vitro 
detection assay. 
HEK293T cells were plated in a six well plate at a concentration of 250,000 
cells/well. After 24 h cells were transfected with pHIL, control plasmid, or with a 
construct coding RLUC8-S257G as a negative control (pTRE-Tight-RLuc8-S257G, 
Addgene, #79844). The day after transfection, cells were trypsinized, resuspended 
and plated in a 96 well plate (96 Well White Polystyrene Microplate, #CLS3610, 
Corning®, Corning, New York, USA) in complete DMEM w/o phenol red 
(#31053028, Life Technologies) and w/o Penicillin/Streptomycin at a concentration 
of 75,000 cell/well. The experiment was performed adding CTZ 400a at increasing 
concentrations (10, 20, 50 µM); the luminescence intensity and the fluorescence of 
RLUC8-S257G and E2GFP were detected using the TECAN 500F machine in the 
Luminescence Dual Color mode (magenta/green filters) under three different pHi 
conditions. Buffers used to change the intracellular pH were composed as follows: pH 
6 buffer: 1mM MgCl2, 10 mM MES, 100 mM KCl, 100 mM NaCl, 1.36 mM CaCl2, 
10 mM glucose, 20 µM nigericin; pH 7.4 and pH 8 buffers: 1mM MgCl2, 10 mM 
HEPES, 100 mM KCl, 100 mM NaCl, 1.36 mM, CaCl2, 10 mM glucose, 20 µM 
nigericin. All experiments were performed at RT in the dark. 
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The BRET ratio was calculated as follows: (I510 / I405)HALO-E2GFP-RLUC8 - (I510 / 
I405)RLUC8 60. 
 
3.7 Time Lapse Live Cell imaging 
Hippocampal neurons were plated on poly-D-lysine-coated 25 mm coverslips, 
transfected with pLenti-CD4/ΔN12 E2GFP-ΔC15 and imaged at 10 DIV. Live cell 
imaging was performed using a Leica SP8 laser scanning confocal microscope 
equipped with a 40x oil immersion objective. The sequential excitation of E2GFP at 
405 nm and 488 nm was achieved with a multiline argon laser. Emitted fluorescence 
was collected between 510 nm and 560 nm using a single photomultiplier tube (PMT) 
at a constant voltage. Before every experiment, coverslips with cells were positioned 
in a chamber and a pH calibration curve was performed by adding in the chamber, 
initially, a K+ enriched buffer composed as follows: 120 mM potassium gluconate, 40 
mM NaCl, 20 mM HEPES, 0.5 mM CaCl2, 0.5 mM MgSO4 pH 7.5. Cells were 
subsequently perfused with the same buffer, adjusted to the desired pH by adding 
HEPES for pH>7, NaOH and MES for pH <7, and supplemented with nigericin 10 
µM and valinomycin 10 µM. The calibration curve was performed at pH 5.5, 6, 6.5, 
7, 7.5. Images were taken 10 min after the addition of the buffer supplemented with 
ionophores (Bizzarri et al.,2006). 
To determine the intracellular pH value during epileptic-like conditions, cells 
were first perfused with a buffer composed as follows: 140 mM NaCl, 2.5 mM KCl, 
1.8 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, 10 mM glucose, pH 7.4. The 
fluorescence was collected for 2 min to obtain the baseline, after which 30 µM 
bicuculline (#0131, TOCRIS, Bristol, UK) was added and fluorescence was collected 
for additional 8 min.  Confocal images were analyzed using the Image J software. 
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First, regions of interest (ROIs) were chosen for each image. The area of each ROI 
was about 2 µm2, positioned on discrete structures visible on neurite extensions. 
Fluorescence intensity ratios were calculated according to the equation R= MV405 / 
MV488, where MV405 (mean value) is the average pixel intensity for each ROI when 
ΔN12-E2GFP-ΔC15 is excited with 405 nm light, while MV488 is the average pixel 
intensity for each ROI when ΔN12-E2GFP-ΔC15 is excited with 488 nm light 
(Chiacchiaretta et al., 2017). 
 
Emission fluorescence ratios were converted to pH values according to the 
calibration curves collected by fitting each ratio value in a sigmoidal dose response 
curve using the Graphpad Prism 7.04 software. 
 
3.8 Intracellular Recordings 
Intracellular recordings were performed on HEK293T cells transfected with 
CMV-pHIL and control plasmids, plated on petri dishes. For all the experiments, cells 
were maintained in extracellular standard solution (Tyrode) containing: NaCl 140 
mM, KCl 4 mM, CaCl2 2 mM, MgCl2 1 mM, HEPES 10 mM, Glucose 10 mM, pH 
7.3 with NaOH. Current-clamp recordings were performed at a holding potential of 0 
mV. The intracellular pH was changed through the patch pipette using an internal 
solution at three different pH: 6, 7.4 and 8. The internal solution was composed by: 
K+ gluconate 126 mM, NaCl 4 mM, MgSO4 1 mM, CaCl2 0.02 mM, Bapta 0.1 mM, 
Glucose 15 mM, HEPES 5 mM, ATP 3 mM, GTP 0.1 mM. For the acidic solution 
(pH 6) HEPES was substituted with MES 5 mM. CTZ 400a and CTZh were added 
directly to the external solution, during the recording, at a final concentration of 
respectively 10 µM and 40 µM. All experiments were performed at RT in the dark. 
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Data acquisition was performed using PatchMaster program (HEKA Elektronic, 
Lambrecht/Pfalz, Germany). 
Voltage-clamp cell-attached recordings were performed at a holding potential 
of -70 mV. Cells were recorded in continuous for 5 min without applying any 
currents in three different external solutions: (i) Tyrode, (ii) Tyrode with bicuculline 
(30 µM) and (iii) Tyrode with bicuculline (30 µM) and CTZ400a (40 µM). Action 






4.1 Molecular Cloning of pHIL and control probes 
a. Engineering of pcDNA-pHIL and pcDNA-ctrl 
To obtain a probe able to reduce neuronal hyperexcitability, we coupled a 
bioluminescent protein with an inhibitory opsin and with a pH sensor to control 
neuronal hyperexcitability upon intracellular acidification, a phenomenon observed 
during epileptic conditions (Ahmed and Connor, 1980; Xiong et al., 2000). The 
resulting chimeric protein was named pHIL, for pH-sensitive Inhibitory Luminopsin. 
pHIL is composed of the enhanced version of Natromonas Pharaonis Halorhodopsin 
(eNpHR3.0) (Gradinaru et al., 2010) the pH-sensitive variant of GFP, E2GFP 
(Bizzarri et al., 2006) truncated at the N terminal and C terminal of 12 and 15 amino 
acids respectively (ΔN12-E2GFP-ΔC15), and the mutated Renilla Luciferase 
truncated at the N terminal of 3 amino acids (ΔN3-RLUC8-S257G, Saito et al., 
2012). Proteins were truncated in order to decrease the space between them, thus 
facilitating the transfer of energy. ΔN12-E2GFP-ΔC15 and ΔN3-RLUC8-S257G are 
linked by two amino acids (Gly and Thr), while ΔN12-E2GFP-ΔC15 is linked to 
eNpHR3.0 by three alanines51,52. The sequences coding eNpHR3.0-ΔN12-E2GFP-
ΔC15-ΔN3-RLUC-8S257G (pHIL) and the control construct ΔN12-E2GFP-ΔC15-
ΔN3-RLUC8-S257G (ctrl) were cloned in pcDNA3.0 under the control of the 
cytomegalovirus promoter (CMV). 
The expected lengths of plasmids obtained from the cloning are 7978 bp for 
pHIL and 7116 bp for the control. To confirm that the cloning was successful,, a 
restriction enzyme digestion was performed. pcDNA-ctrl was digested with BAMHI, 
EAGI and SALI restriction enzymes obtaining bands of: 7116 bp (BAMHI), 1269 bp 
and 5847 bp (EAGI), 2188 bp and 4928 bp (SALI) [Figure 7A]. pcDNA-pHIL was 
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digested with XBAI, EAGI, and SALI restriction enzymes obtaining bands of: 7978 
bp (XBAI), 2915 bp and 5063 bp (EAGI); 2188 bp and 5790 bp (SALI) [Figure 7B]. 
The results of plasmids digestions confirmed that the cloning was successful. 
 
b. Engineering of pAAV2-pHIL and pAAV2- ctrl 
In order to produce a tool suitable to be used both for in vitro experiments on 
primary neurons as well as for in vivo experiments, sequences coding pHIL and ctrl 
probes were cloned in an AAV2 vector under the control of the Ca2+/Calmodulin-
dependent kinase IIɑ (CaMKIIɑ) promoter to have the expression only in excitatory 
neurons of the postnatal forebrain39. It is known that AAVs cargo capacity is 
between 4.1 and 4.9 kb61. In order to create a transgene that is short enough to be 
compatible with AAV limited packaging capacity, a truncated and shorter version of 
the CamKIIɑ promoter was used, which is about 0.3 Kb, compared to 1.3 Kb of the 
original promoter62 . This shorter sequence was inserted upstream of the pHIL and 
ctrl sequences in the AAV2 vector. The expected length of plasmids is 6943 bp for 
pHIL and 6078 bp for the control. To confirm that, the cloning was successful, a 
restriction enzyme digestion was performed. pAAV2-ctrl was digested with ECORI, 
KPNI, PVUII and NOTI restriction enzymes obtaining bands of: 6078 bp (ECORI), 
699 bp and 5379 bp (KPNI), 2619 bp and 3459 bp (PVUII), 2887 bp and 3191 bp 
(NOTI) [Figure 7C]. pAAV2-pHIL was digested with ECORI, PVUII, and NOTI 
restriction enzymes obtaining bands of: 6943 bp (ECORI), 2619 bp and 4324 bp 
(PVUII), 2799 bp, 2887 bp and 1257 bp (NOTI) [Figure 7D]. The results of plasmids 




c. Engineering of pLenti-CD4/E2GFP 
pHIL is activated only under acidic conditions. It is known that, during seizure 
activity, neurons accumulate H+, resulting in acidification of the intracellular 
space16. In order to study activity-induced intracellular acidification in primary 
hippocampal neurons, pLenti-CD4/E2GFP was constructed. ΔN12-E2GFP-ΔC15 was 
cloned downstream of the human cluster of differentiation 4 (CD4) receptor 
transmembrane sequence, to target the E2GFP to the intracellular side of the plasma 
membrane, under the control of the human ubiquitin promoter (hUb), in a lentiviral 
vector (pLenti). The expected length of plasmid obtained is 11280 bp. To confirm 
that the cloning was successful, a restriction enzymes digestion was performed. 
pLenti-CD4/E2GFP was digested with BAMHI, EAGI and SACII restriction 
enzymes obtaining bands of: 11280 bp (BAMHI), 7258 bp and 4022 bp (EAGI), 3834 
bp and 7446 bp (SACII) [Figure 7E]. The results of plasmids digestions confirmed 























Figure 7. Cloning products restriction enzymes digestion. Agarose gels illustrating the 
products of  pcDNA-pHIL (A), pcDNA-ctrl (B), pAAV2-pHIL (C), pAAV2-ctrl (D) and 




4.2 Validation of pHIL and ctrl expression and localization in 
HEK293T cells. 
HEK293T cells were transfected with the constructs (pcDNA-pHIL and 
pcDNA-ctrl) [Figure 8A] and their expression and localization was verified. Western 
blot analysis was performed by using antibodies against Rluc8. As shown in [Figure 
8B], the fusion proteins show a molecular weight of 93 kDa and 62 kDa respectively, 
as expected. In order to verify the localization of the two probes, confocal live cell 
imaging was performed. HEK293T were transfected with the two constructs and 
subsequently treated with CellMask Deep Red (see material and methods) for plasma 
membrane staining. Colocalization of pHIL with the plasma membrane was observed 
[Figure 8C upper panel], while the ctrl construct was observed in the cytoplasm, as 





Figure 8. pHIL and control constructs structure, expression and localization in 
HEK293T cells. (A) Schematic illustration of pHIL and control constructs. For details, see 
text. Both fusion proteins were cloned into pcDNA3.0 under the control of the 
cytomegalovirus promoter (CMV). (B) Western blot showing pHIL and control expression 
(arrowheads) in HEK293T cells. The expression of the fusion proteins was analyzed using 
anti-RLuc antibodies. Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies 
were used to verify equal loading. (C) Representative confocal images showing membrane 
localization of pHIL (upper panel) and cytoplasmic localization of the control construct 
(lower panel). Cell Mask was used as a marker of plasma membrane (red channel). Scale 










4.3  Analysis of the light cascade steps leading to the activation of 
pHIL. 
The activation of pHIL is based on a light cascade that culminates in the 
activation of eNpHR3.0. After the addition of coelenterazine 400a (CTZ 400a), ΔN3-
RLUC8-S257G is activated and emits 405 nm light. UV light, under acidic 
conditions, activates the pH sensor ΔN12-E2GFP-ΔC15 that emits 510 nm light 
(BRET). The light emitted by ΔN12-E2GFP-ΔC15 in turns activates eNpHR3.0 
(FRET) to hyperpolarize neurons [Figure 9A]. 
In order to better characterize the function of pHIL, every step of the light 
cascade, from the addition of CTZ 400a to the activation of eNpHR3.0, was analyzed. 
First the BRET efficiency was measured at acidic (pH 6) and alkaline pH (pH 8) with 
respect to the physiological condition (pH 7.4). HEK293T cells were transfected with 
pHIL or with a construct coding ΔN3-RLUC8-S257G only as a negative control; 
CTZ 400a was added at increasing concentrations and the intensity of the 
luminescence emitted by ΔN3-RLUC8-S257G (405 nm) and of the fluorescence 
emitted by ΔN12 E2GFP ΔC15 (510 nm) was measured using the TECAN 500F 
machine. After this, the BRET ratio was calculated as follows: (I510 / I405)HALO-E2GFP-
RLUC8 - (I510 / I405)RLUC8. As reported in [Figure 9B], BRET ratio values are higher at 
pH 6 than at pH 8 and pH 7.4 indicating that the energy transfer between ΔN3-
RLUC8-S257G and ΔN12-E2GFP-ΔC15 is higher under acidic conditions, consistent 
with the increased absorbance of E2GFP in the acidic environment. To justify these 
results, we analyzed in detail every step of the light cascade starting with the analysis 
of the 405 nm light emitted by the ΔN3-RLUC8-S257G at pH 6 and at the control pH 
(7.4). The analysis was done in cells transfected with the ctrl construct in order to 
consider the BRET event first. In the graph is shown that the ΔN3-RLUC8-S257G 
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emission at pH 6 is lower with respect to control pH. This is because the light emitted 
is absorbed by the E2GFP in the acidic environment [Figure 9C]. 
The second step of the light cascade is the FRET between ΔN12-E2GFP-ΔC15 and 
eNpHR3.0. To analyze this step, E2GFP total emission was measured in cells 
transfected with pHIL and ctrl plasmids setting the pH to 6 and 7.4 and adding 
increasing concentrations of CTZ400a. In the graph shown in [Figure 9D], is clear 
that, under acidic conditions, E2GFP total emission is lower in cells transfected with 
pHIL with respect to cells transfected with the ctrl construct at pH 6. This is because 
the light emitted by E2GFP is absorbed by eNpHR3.0 in the pHIL probe, and not 
absorbed in the ctrl probe. For the control pH, the E2GFP total emission for the 
control construct is lower with respect to pH 6 because in neutral pH the E2GFP will 
adsorb a smaller amount of light coming from the ΔN3-RLUC8-S257G. Finally, the 
E2GFP total emission in cells transfected with pHIL is higher for the control pH with 
respect to the pH 6. This is because the light emitted by E2GFP will be absorbed by 








Figure 9. Characterization of pHIL light cascade mechanism. (A) Schematic illustration 
of pHIL functioning, showing: (i) the activation of ΔN3-RLUC8-S257G after the addition of 
CTZ400a and the consequent emission at 405 nm; (ii) under acidic conditions the light 
emitted by ΔN3-RLUC8-S257G activates ΔN12-E2GFP-ΔC15 that will emit at 510 nm 
(BRET); (iii) the light emitted by ΔN12-E2GFP-ΔC15 activates eNpHR3.0 (FRET). (B) Plot 
of BRET ratio from HEK293T cells transfected with pHIL after the addition of CTZ 400a 
(10, 20 and 50 µM) and under different pH conditions. Mean ± SEM, n=4 indipendent 
preparations, p>0,05 one-way ANOVA. (C) Plot of  ΔN3-RLUC8-S257G emission from 
HEK293T cells transfected with ctrl constructs after the addition of CTZ 400a (10, 20 and 50 
µM) at pH 6 and 7.4. Mean ± SEM, n=4 indipendent preparations, p>0,05 one-way ANOVA. 
(D) Plot of E2GFP total emission from HEK293T cells transfected with pHIL and ctrl 
constructs after the addition of CTZ 400a (10, 20 and 50 µM) and at pH 6 and 7.4. Mean ± 











4.4 Electrophysiological characterization of pHIL in HEK293T 
cells. 
 
In order to analyze if, after the addition of CTZ 400a, the light emitted by 
ΔN12-E2GFP-ΔC15 under acidic conditions is able to activate eNpHR3.0, HEK293T 
cells were transfected with pHIL and ctrl constructs and electrophysiological 
recordings were performed upon addition of CTZ 400a (10 µM) and by changing 
intracellular pH through the patch pipette. Plasma membrane hyperpolarization was 
observed at acidic intracellular pH (pH 6), while no hyperpolarization was observed 
at physiological (pH 7.4) and alkaline (pH 8) pH in cells transfected with pHIL 
[Figure 10A, 10B]. In cells transfected with the control construct, no 
hyperpolarization was observed under any pH condition [Figure 10C]. In order to 
confirm that the activation of pHIL occurs only when ΔN12-E2GFP-ΔC15 absorbs 
the 405 nm light coming from ΔN3-RLUC8-S257G, electrophysiological recordings 
were performed in HEK293T cells transfected with pHIL and ctrl probes by changing 
intracellular pH and upon addition of CTZ h (20 µM) , which causes ΔN3-RLUC8-
S257G to emit at 488 nm, which should not activate ΔN12-E2GFP-ΔC15 under acidic 
conditions. Accordingly, no hyperpolarization was observed in cells transfected with 
pHIL [Figure 10D] or the ctrl probe [Figure 10E] under any of the tested pH 
conditions. This is because ΔN3-RLUC8-S257G is too far to activate eNpHR3.0, and 






Figure 10. Determination of pHIL activity in HEK293T cells. (A-B) Representative plots 
of current clamp recordings (mV/s) from HEK293T cells expressing pHIL show plasma 
membrane hyperpolarization in response to CTZ 400a (10 µM) and upon intracellular 
acidification (A). The graph in (B) shows the absence of hyperpolarization in HEK293T 
expressing the ctrl probe. Mean ± SEM of n=12, 9, 8 cells for pH 6, 7.4 and 8, respectively;  
** p<0.01, *** p<0.001, one-way ANOVA followed by Bonferroni’s post-hoc test. (C-D) 
Representative plots of current clamp recordings from HEK293T cells expressing pHIL (C) 
or the ctrl probe (D) show no plasma membrane hyperpolarization in response to 
coelenterazine h (20 µM) and after intracellular acidification. Mean ± SEM of n=6 cells. 
p>0.05, one-way ANOVA.  
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4.5 Validation of pHIL and ctrl -expressing AAVs expression and 
localization in primary hippocampal neurons. 
After the cloning of pAAV2-pHIL and pAAV2- ctrl, AAV2/9 particles were 
produced (TIGEM, AAV Vector Core) and primary hippocampal neurons infected. 
First, a western blot analysis was performed by using antibodies against E2GFP. As 
shown in [Figure 11B], the fusion proteins have a molecular weight of 93 kDa and 
62 kDa respectively, as expected. In order to verify the localization of the two probes, 
neurons expressing pHIL or the ctrl probe were fixed and stained with antibodies 
against E2GFP. Confocal microscopy analysis revealed the localization of pHIL in 
correspondence of the plasma membrane [Figure 11C lower panel], while the ctrl 





Figure 11. pHIL and pHIL control structure, expression and localization in 
hippocampal neurons. (A) Schematic illustration of pHIL and control AAV constructs. For 
details see text. Both fusion proteins are expressed under the control of the truncated form 
(0.3 Kb) of the CaMKII promoter. (B) Western blot analysis of hippocampal neurons 
expressing pHIL and control. The expression of the fusion proteins (arrowheads) was 
analyzed using anti-GFP antibodies. Anti-alpha actin antibodies were used to verify equal 
loading. (C) Representative confocal images showing the membrane localization of pHIL 
(lower panel) and the cytoplasmic localization of the control probe (upper panel). E2GFP 
fluorescence, green channel; Hoechst-labeled nuclei, blue channel. Scale bars: 25 µm for 





4.6 Analysis of pHi changes during epileptic like conditions. 
pHIL is activated only under acidic conditions. It is known that, during seizure 
activity, neurons accumulate H+, resulting in acidification of the intracellular space 
(Xiong et al., 2000). To test the activation of pHIL also in hippocampal neurons, we 
used bicuculline, a competitive antagonist of GABAA receptors. Recent studies 
described the bicuculline-induced extracellular acidification at cell bodies and at 
synapses (Chiacchiaretta et al., 2017). Following a similar approach, we tested 
whether bicuculline was able to induce also an intracellular acidification. To do this, 
we engineered the pH sensor E2GFP to monitor intracellular pH shifts (pHi). ΔN12-
E2GFP-ΔC15 was inserted downstream of the human cluster of differentiation 4 
(CD4) receptor transmembrane sequence, to target the E2GFP to the intracellular side 
of the plasma membrane, under the control of the human ubiquitin promoter (hUb), in 
a lentiviral vector (pLenti) [Figure 12A]. 
The reason for which we cannot use pHIL to monitor intracellular pH shifts in 
plasma membrane is that the eNpHR3.0 will absorb the great part of the light emitted 
by the ΔN12-E2GFP-ΔC15, hiding the possible bicuculline effect. 
 First, a western blot analysis was performed in order to analyze the expression 
of CD4--ΔN12-E2GFP-ΔC15 and control (E2GFP only from pcDNA-E2GFP, 
provided by Dr. Bizzarri, University of Pisa) in HEK293T cells by using antibodies 
against E2GFP. As shown in [Figure 12B], the fusion protein has a molecular weight 
of 78 kDa, as expected. In order to verify the localization of the probe, confocal cell 
imaging was performed in HEK293T cells and primary hippocampal neurons 
transfected with the pLenti-CD4-ΔN12-E2GFP-ΔC15 and control plasmids. Cells 
were fixed and stained with antibodies against E2GFP. Confocal microscopy analysis 
revealed the localization of CD4-ΔN12-E2GFP-ΔC15 in correspondence of the 
plasma membrane both in in HEK293T cells and in primary hippocampal neurons 
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[Figure 12C and D, upper panel], while the ctrl probe was observed in the cytoplasm 
[Figure 12C and D, lower panel]. 
Time-lapse confocal live cell imaging was subsequently used to study 
bicuculline-induced intracellular acidification in hippocampal neurons. Hippocampal 
primary neurons were plated on 25 mm poly-L-lysine coated glass coverslips and 
after 7 DIV were transfected with pLenti-CD4-ΔN12-E2GFP-ΔC15. The bicuculline 
treatment was performed at DIV 10, changes in fluorescence were monitored and pH 
values were subsequently extrapolated from ratio values using a calibration curve 
created before every experiment. A scheme of the time course of the experiments is 
shown in [Figure 12E]: pH was first measured under baseline conditions (2 min), 
then network hyperactivity was induced by blocking GABAA receptors with 
bicuculline (30 µM) and cultures were imaged for further 8 min. An increase in 
E2GFP fluorescence (λex = 405 nm) was observed during the bicuculline treatment, in 
correspondence of discrete spots along neurite extensions [Figure 12F]. To quantify 
the variation in fluorescence intensity, regions of interest (ROIs) of about 2 μm were 
drawn around the spots in the neurite extensions, and mean fluorescence intensity 
values were calculated for every image at every time point for the 405 nm and 488 
nm excitation. Emission fluorescence ratios were converted to pH values according to 
the calibration curves collected by fitting each ratio value in a sigmoidal dose 
response curve using the Graphpad Prism 7.04 software. [Figure 12G] shows pHi 
variations upon the addition of bicuculline. Under basal conditions pHi was 7.3, while 
in the presence of bicuculline pHi values constantly dropped to reach a plateau value 
of 6.1 after about 7 min. 
To demonstrate that the decrease in pH is due to the bicuculline action and not 
to the bleaching effect, live cell imaging of hippocampal neurons transfected with 
pLenti-CD4-ΔN12-E2GFP-ΔC15 was performed for 10 minutes without the addition 
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of bicuculline. [Figure 12H] show no decrease in pH during all the experiment 







Figure 12. pHi variations under epileptic-like conditions. (A) Schematic illustration of the 
Ub-CD4/E2GFP probe. For details, see text. The fusion protein expression is under the 
control of the human ubiquitin promoter. (B) Western blot analysis of HEK293T cells 
expressing CD4/E2GFP and control (E2GFP only) probes. The expression of the fusion 
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proteins was analyzed using anti-GFP antibodies. Anti-alpha actin antibodies were used to 
verify equal loading. (C-D) Representative confocal images of the membrane localization of 
CD4/E2GFP in HEK293T cells and in hippocampal neurons (C, D, left). As a control, the 
cytoplasmatic E2GFP was used (C, D right). E2GFP fluorescence, green channel; Hoechst-
labeled nuclei, blue channel. Scale bars: 20 µm in lower magnification images; 5 µm in 
higher magnification images. (E) Schematic representation of the time course of a typical 
experiment with the addition of bicuculline (30 µM) after 2 min of imaging under basal 
conditions. (F) Representative fluorescence (λex = 405 nm) images taken from neurons under 
basal conditions (t = 0 min) and after bicuculline treatment (t = 10 min). ROIs used for 
quantification are indicated in the high-magnification images (indicated by arrows). Scale 
bars, 20 µm for low magnification images and 5 µm for high magnification images. 
(G) The graph illustrates pH variations upon bicuculline (30 µM) addition. pHi 
decreases as a function of time in discrete spots along cell extensions. Mean ± SEM, 
n=7 independent preparations, * p< 0.05 compared to basal levels (0-2 min) One way 
ANOVA for repeated measures, followed by Friedman’s post-hoc test. (H) The graph 
illustrates possible pH variations due to the bleaching effect during the entire time of 




















4.7 Electrophysiological characterization of pHIL in primary 
hippocampal neurons. 
Bicuculline is able to induce intracellular acidification and to mimic the 
epileptic phenotype increasing hippocampal neurons excitability. In order to analyze 
the functioning of pHIL in primary neurons, primary hippocampal neurons were 
infected with the AAV2/9 pHIL and cell-attached voltage-clamp recordings was 
performed after treatment with tyrode alone [Figure 13A], tyrode with bicuculline 
(30 µM) [Figure 13B] and tyrode with bicuculline (30 µM) and CTZ400a (40 µM) 
[Figure 13C]. The cell attached electrophysiological technique was used instead of 
patch clamp, as the latter involves the buffering of neuronal cytoplasm, which would 
abolish bicuculline-induced intracellular acidification, thus impairing the activation of 
the probe. 
Preliminary data suggest that pHIL activation is able to reduce bicuculline-
induced excitability in primary neurons, in particular the number of bursts [Figure 
13D], the intra-burst frequency [Figure 13E] and the number of intra-burst events 
[Figure 13F] are decreased after the treatment with bicuculline and CTZ400a with 





Figure 13. pHIL activation inhibits bicuculline-induced hyperexcitability in 
hippocampal neurons. Representative traces of cell-attached voltage-clamp recordings of 
primary hippocampal neurons infected with AAV2/9-pHIL in the presence of tyrode (A), 
bicuculline 30 µM (B), and bicuculline 30 µM + CTZ400a 40µM (C). Graphs show number 
of burst (D), intraburst frequency (E) and number of intraburst events (F) under the three 





Seizures are temporary changes of neuronal activity in the brain characterized 
by high neuronal excitability, and when repeated chronically, they are a typical 
symptom of epilepsy. A number of drugs are currently available to reduce the 
hyperexcited state in epileptic patients, but unfortunately, in many cases medications 
are unable to adequately control seizures. For many “drug resistant” patients the 
surgery can significantly reduce or eliminate seizures but for the other part of them 
seizures continue to impair their daily life.  
An alternative option to control seizures can be the brain stimulation of various 
brain areas. Open loop neural stimulation such as VNS (vagus nerve stimulation), 
TNS (trigeminal nerve stimulation) or DBS (deep brain stimulation) consist in the 
application of electric currents to seizure-generating circuitries in a continuous mode 
and have been shown to reduce seizure frequency after two years63. Although such 
open loop neuromodulation is in some cases efficient to treat seizures, it involves the 
long-term continuous stimulation and it can affect many parts of the brain increasing 
the possible risk of side effects.  
A possible alternative is the closed loop neuromodulation. In this case the 
system delivers stimulation through electrodes placed in brain areas shown to 
generate seizures. The stimulation starts when it detects, through the EEG, the 
beginning of seizure activity. It is known that closed loop transcranial cortical 
stimulation in rats consistently interrupt seizures for six weeks, reduce the seizure 
duration and more importantly no adverse effects are observed on the 
electrophysiologic activity of the brain after the treatment64. However, despite many 
positive effects of the closed loop neurostimulation, significantly higher seizure rate 
64 
 
is still observed during the treatment and a high rate of complications are reported 
within the first month of implantation65. 
Despite important advancements, refractory epilepsies still represent a serious 
problem. For this reason, novel possible approaches for epilepsy treatment are being 
investigated, amongst which gene therapy. Gene therapy in the nervous system 
involves the transfer and the expression of particular genes in brain cells using mainly 
adeno associated viral vectors (AAV). Genes transferred in neurons after viral 
infection may code for proteins able to modulate neuronal activity. This is the case of 
opsins and optogenetics. Optogenetics provide immediate transient control of specific 
cell populations using light sensitive proteins, named opsins38.In vitro and in vivo 
studies indicate that optogenetics can be used to control seizure activity46. Moreover, 
recently, closed loop neuromodulation has been combined to optogenetics. In this 
case, in mice expressing two different opsins (ChR and HR), seizures can be detected 
in real time and stopped. The detection of seizures in real time is due to implantation 
of intrahippocampal depth electrodes and optogenetic mediated seizures control is 
due to the activation of opsin mediated by individual optical fibers47 . 
The very important concept at the basis of the optogenetic approach is the 
precise spatiotemporal wavelength-specific illumination that is achieved, usually, 
using optical fibers or using LED light sources. However, the implementation of such 
techniques requires specialized equipment, the surgical implantation is very invasive 
and, above all, the optogenetic approach is restricted to small volumes of the brain 
because of the difficulty to illuminate deep brain areas. In this scenario, luminopsins 
get ahead53. Luminopsin can modulate neural activity in a closed loop fashion and 
thus be activated only when it is needed through direct opsin stimulation or upon 
addition of luciferase substrate. This last aspect is important because it could provide 
an alternative to the use of external light sources used to activate opsins. It is known 
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that luminopsins can be used to suppress in an efficient way epileptic seizures in both 
vitro and in vivo51. In this last case is demonstrated that after the addition of the 
chemical compound able to activate luminopsin (coelenterazine), neuronal activity is 
suppressed in excitatory neurons expressing the luminopsin51. In this thesis, we want 
to implement a similar strategy to try to control epileptic seizures. 
We aimed to engineer a probe in which a bioluminescent protein was coupled 
with an inhibitory opsin, the Natromonas Pharaonis Halorhodopsin, with the purpose 
of reducing the hyperexcitability of excitatory neurons under epileptic conditions. 
The expression of the probe is confined to excitatory neurons thanks to the use of the 
specific CaMKIIɑ promoter. Moreover, this model is constructed on the model of the 
closed loop neurostimulation because the inhibition of excitatory neurons expressing 
the probe occurs when and where needed, upon neurons intracellular acidification, 
phenomenon observed during epileptic conditions15,16, thanks to the pH-sensitive 
variant of GFP, E2GFP22 . Thus, the chimeric protein called pH sensitive inhibitory 
luminopsin (pHIL) was engineered. It takes advantage of the BRET mechanism 
between the RLuc8 and the E2GFP to increase the power density of emitted light52 
directed to the eNpHR3.0 and to give to the probe pH sensitivity. The pH sensitivity 
is linked not only to the acidic environment but also to the wavelength of the light 
emitted by the luciferase. For this reason, the search of a specific variant of the 
luciferase substrate is the key point at the base of the functioning of the probe. E2GFP 
is able to emit green light (λem=510 nm) in an acidic environment upon illumination 
with 405 nm light. RLuc8 is able to emit near-UV light upon reaction with the 
coelenterazine variant CTZ400a57. 
Neurons transduced with pHIL are in principle unaffected in the absence of the 
specific substrate and only affected when the substrate is present, thereby avoiding 
permanent alteration of their properties and then, interestingly, the near-UV emission 
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is a transient effect (in the order of few minutes) linked to the reaction of CTZ400a 
with the RLuc8 enzyme. This is a great advantage because, in this way, it should not 
be deleterious to neurons and to the brain. Using this substrate, pHIL is able to 
hyperpolarize HEK293T cells specifically under acidic conditions upon addition of 
CTZ400a, despite it is known that E2GFP is able to emit a bit also in a neutral pH22.In 
this case, however, the fluorescence emitted by E2GFP is not enough to activate 
eNpHR3.0 (Fig.10B). It is remarkable that the quantity of light emitted, the 
hyperpolarization rate and the time of pHIL activation depend on the probe 
expression at plasma membrane but also on the CTZ400a concentration used. This is 
interesting because, when pHIL is expressed in excitatory neurons, we can obtain the 
modulation of neuronal activity by limiting CTZ400a concentration. This should 
avoid the risk of changing GABAA receptor reversal potential, mediated by 
eNpHR3.0 after photostimulation, which may result in increased excitability66. 
pHIL can therefore be considered a promising chemo-genetics approach to 
achieve cell-specific on demand seizure suppression. Such approach is reminiscent of 
the DREADD (Designer Receptors Exclusively Activated by Designer Drugs) 
technology that has been used to treat and attenuate focal neocortical seizures67.The 
DREADD approach is based on the cell-specific expression of a receptor that is 
activated by a drug, the clozapine-N-oxide (CNO). Despite the use of DREADDs is 
promising, their use has some disadvantages. For example, DREADDs need the 
activation of secondary endogenous signaling proteins (G proteins), which should be 
present in every target population of neurons; the effects of DREADD activation can 
have very diverse and undesired effects other than altering membrane conductance; 
clozapine (CNO) metabolism has multiple effects on the brain and for this reason 
clinical translation is prohibitive51 . 
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This is not the case of pHIL. Everything required to manipulate neural activity 
is encoded in a single molecule; CTZ h and CTZ400a are used for in vivo imaging 
and no side effects have been reported52,68 ;no downstream side-effects re reported 
after the activation of luminopsins51. Despite many advantages, some aspects may 
make the translational clinical application of pHIL to treat epilepsy difficult, the most 
important being the use of the gene therapy. Gene therapy would involve the use of 
viral vectors, in our case, adeno associated viral vectors, which can be immunogenic. 
Furthermore, the expression of opsins, in our case of eNpHR3.0, can be difficult 
because the opsin derive from Natronomonas Pharaonis, an archaea evolutionarily far 
from humans. 
In conclusion, in this thesis we propose a very interesting and exciting chemo-
optogenetic approach to detecting and potentially treating epileptic seizures. This 
approach could sign the way of closed loop therapies for the treatment of drug 
resistant epilepsies.  
In the first part of the work, we engineered pHIL and characterized it, with 
success, in cell lines (HEK293T). The following step was to characterize it also in 
primary hippocampal neurons. To do this we characterized bicuculline-induced 
intracellular acidification, which localized to discrete boutons, where pHi decreased 
as a function of time. Using the bicuculline model, it is therefore possible to analyze 
the capability of pHIL to modulate the hyperexcitated state in primary neurons in 
vitro. 
In this case, the cell-attached electrophysiological technique was used to avoid 
the buffering of neurons intracellular side using the classic patch clamp technique, 
which would abolish the bicuculline induced intracellular acidification necessary to 
activate the probe. Preliminary data suggest that in primary hippocampal neurons 
infected with AAV2/9-pHIL, the addi tion of CTZ400a is able to reduce the 
68 
 
bicuculline-induced increase the number of bursts, the intraburst frequency and the 
number of intraburst events with respect to basal conditions (tyrode). Remarkably, 
pHIL activation reduced the previously described parameters to a value similar or 
lower with respect to the basal condition. The analysis of pHIL capability to modulate 
bicuculline-induced hippocampal neurons hyperactivation is a work in progress. 
Another ongoing experiment is that to analyze the effect of pHIL by looking at the 
network activity of neurons infected with the AAV2/9- pHIL using Multi Electrode 
Arrays (MEA).  
For the in vivo characterization of pHIL, first the expression and the 
localization of the probe in the hippocampal cells will be studied. This goal will be 
achieved through the stereotaxic injection of AAV2/9 particles carrying pHIL in the 
dorsal hippocampus. Then, in order to know how much time CTZ400a needs to reach 
the dorsal hippocampus and activate pHIL, live bioluminescence imaging on 
AAV2/9-pHIL injected mice will be performed. This goal is indispensable because 
we need to determine the time window in which we can inject the kainic acid and to 
induce seizures, mimicking the temporal lobe epilepsy. Temporal lobe epilepsy will 
be reproduced after injection of kainic acid in the hippocampus of mice expressing 
pHIL. The pHIL mediated control of epileptic activity induced by kainic acid will be 
possible upon injection of CTZ400a, which is able to cross the blood brain barrier68. 
We will demonstrate to what extent pHIL is able to control seizures by employing 
behavioural tests and EEG recordings in pHIL- and Ctrl injected mice.  The in vivo 
experiments will provide support to the hypothesis that chemogenetics can be 
effectively used to modulate seizure propagation, thus laying the basis for the 
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